Silexion Therapeutics Corp. (SLXN) stock is experiencing a surge in pre-market trading, climbing over 21.72% on Tuesday. This bullish momentum follows the company’s announcement of new findings from its Phase 2 trial for LODER, its first-generation product designed to combat pancreatic cancer. The updated analysis reveals a remarkable 56% objective response rate (ORR) in patients treated with LODER. This figure rises even further to 67% for those patients whose previously unresectable tumors became eligible for surgical removal.
These results build upon Silexion’s previous report that patients receiving LODER in conjunction with standard-of-care (SoC) chemotherapy demonstrated a 9.3-month improvement in overall survival (OS) compared to chemotherapy alone. The new data now underscores LODER’s additional potential to enhance tumor resectability, thereby expanding surgical options for individuals with otherwise inoperable pancreatic cancer.
Silexion is also advancing the development of its next-generation product, SIL-204. Building upon the efficacy of LODER, SIL-204 is engineered to target a wider spectrum of KRAS mutations, promising even greater treatment capabilities. In August, Silexion Therapeutics merged with Moringa Acquisition Corp, a publicly-traded special purpose acquisition company, and Biomotion Sciences. The resulting company, now known as Silexion Therapeutics, continues to push the boundaries of pancreatic cancer treatment with its innovative therapies.
The stock’s upward trajectory is evident, with SLXN trading at $0.91 during the premarket session, reflecting an 18.3% increase. The positive news surrounding LODER’s efficacy has fueled optimism for Silexion Therapeutics and its potential to make a significant impact in the fight against pancreatic cancer.
